Biotechnology

Arcellx

Gilead Completes Acquisition of Arcellx for $7.8 Billion

Gilead Sciences Extends Arcellx Offer Deadline to April 24th

Arcellx released FY2025 Annual Earnings on February 26 (EST), actual revenue USD 22.29 M (forecast USD 33.73 M), actual EPS USD -4.0659 (forecast USD -4.0405)

Arcellx released FY2025 Q4 earnings on February 26 (EST), actual revenue USD 1.654 M (forecast USD 13.4 M), actual EPS USD -1.0038 (forecast USD -1.0236)

Gilead Sciences Announces Acquisition of Arcellx

Arcellx CFO Sells Company Stock

Arcellx Inc. to Present Anito-cel Preclinical Results at Tandem Meeting

Piper Sandler Analyst Maintains Buy Rating on Arcellx Inc

Arcellx Inc. reports positive results for multiple myeloma treatment drug clinical trial

Canaccord Genuity Reiterates Buy Rating on Arcellx

Guggenheim Analyst Maintains Buy Rating on Arcellx

Arcellx Inc. Shows Positive Results in Anti-cell Therapy Trial

Cantor Fitzgerald Downgrades Arcellx Inc. 2025 EPS Forecast

Morgan Stanley Maintains Buy Rating on Arcellx Inc Based on Promising CAR-T Therapy

Evercore ISI Analyst Maintains Buy Rating on Arcellx Inc

Arcellx released FY2025 9 Months Earnings on November 5, 2025 (EST) with actual revenue of USD 20.63 M and EPS of USD -3.0555

Arcellx released FY2025 Q3 earnings on November 5 (EST), actual revenue USD 4.949M (forecast USD 10.3M), actual EPS USD -0.9857 (forecast USD -1.0384)

Tyler Van Buren Reiterates Buy Rating on Arcellx, Anticipates BLA Submission in Mid to Late 2026

Arcellx Inc. Reports Q3 2025 Net Loss of $55.8 Million

Graybosch Analyzes and Recommends Healthcare Stocks, Arcellx Inc Gets a Buy Rating

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ACLX

Cantor Fitzgerald has reiterated a "neutral" rating on Arcellx (NASDAQ: ACLX) shares. Other analysts have also weighed in, with Wells Fargo downgrading the stock to "equal weight" and setting a price target of $115. Canaccord Genuity and Evercore also set the same price target. The stock is currently trading at $115.07, with an average rating of "Hold" and a price target of $111.87. Arcellx reported earnings of ($1.01) per share, meeting estimates, with revenue of $1.65 million, significantly below expectations. Insider Rami Elghandour sold shares, reducing his stake by 24.57%.

Market Beat

Cantor Equity Partners

Cantor Equity Partners IV

Wells Fargo

Evercore

UBS Group AG

Nasdaq

Prudential financial

Cantor Equity Partners VI

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Prudential Financial Pref Share PRS 5.625 08/15/58

Prudential Financial Pref Share PFH 4.125 09/01/25

Prudential Financial Pref Share PRH 5.95 09/01/62

Arcellx's (ACLX) "Neutral" Rating Reiterated at Cantor Fitzgerald

Arcellx Inc. has been acquired in a cash-and-contingent value right (CVR) deal, going private after a tender offer of $115 per share plus a CVR worth up to $5, contingent on sales of its anito-cel product. The merger, completed on April 28, 2026, resulted in Arcellx becoming a wholly owned subsidiary, with significant changes in corporate governance. The company will delist from Nasdaq and terminate SEC reporting obligations. Analysts rate ACLX stock as a Hold with a price target of $115, reflecting a balanced view on its fundamentals and market support.

Tip Ranks

Arcellx Acquired in Cash-and-CVR Deal, Going Private

Truist Financial upgraded Arcellx (NASDAQ:ACLX) to a "strong-buy" rating. Other analysts have mixed views, with TD Cowen downgrading it to "hold" and Guggenheim lowering its price target. The stock opened at $115.10, with a 1-year range of $47.86 to $115.13. Arcellx reported a quarterly loss of ($1.01) EPS, missing revenue expectations. Insiders sold shares, and institutional investors hold 96.03% of the stock. Arcellx focuses on developing cell therapies for oncology and autoimmune diseases.

Truist Financial

Arcellx (NASDAQ:ACLX) Upgraded to Strong-Buy at Truist Financial

GILD

IBBQ

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | ACLX Stock News

StockTitan

Gilead Sciences, Inc.

Gilead Sciences

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VG Health

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

iShares US Pharma

VanEck Biotech ETF

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | ACLX Stock News

Gilead Sciences, Inc. has received all necessary regulatory approvals for its acquisition of Arcellx and has extended the tender offer for Arcellx's shares until April 27, 2026. The offer price remains at $115.00 per share plus a contingent value right. As of April 16, 2026, approximately 10.27 million shares, or 17.5% of outstanding shares, have been tendered. Gilead aims to strengthen its U.S. operations and continues to invest globally in innovative medicines.

Computershare Limited

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer | GILD Stock News

Gilead Sciences has made significant acquisitions, including Arcellx and Ouro Medicines, and secured licensing options with Cartography Biosciences and Kymera Therapeutics, shifting its focus towards oncology and advanced therapies. The company's stock, currently at $142.09, has seen a 16.9% year-to-date increase and a 43.9% rise over the past year. Analysts suggest a modest upside potential, with shares trading below fair value. However, concerns about high debt levels and recent stock price declines remain. Investors are encouraged to monitor clinical milestones and revenue updates.

Simplywall

Kymera Therapeutics

Gilead’s Deal Spree Shifts Pipeline Toward Oncology And Potential Upside

Arcellx(ACLX.US)

Arcellx's (ACLX) "Neutral" Rating Reiterated at Cantor Fitzgerald

Arcellx Acquired in Cash-and-CVR Deal, Going Private

Arcellx (NASDAQ:ACLX) Upgraded to Strong-Buy at Truist Financial

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | ACLX Stock News

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer | GILD Stock News

Gilead’s Deal Spree Shifts Pipeline Toward Oncology And Potential Upside